Roivant Sciences (ROIV)
28.78
+0.29 (1.02%)
Upcoming Events
Latest Headlines
Roivant Sciences (ROIV) PT Raised to $36 at Guggenheim
May 26, 2026 6:38 AM - StreetInsider
Form 4 Roivant Sciences Ltd. For: May 20 Filed by: Venker Eric
May 22, 2026 6:26 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: May 20 Filed by: Pulik Richard
May 22, 2026 6:22 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
May 22, 2026 4:01 PM - SEC Filing
Piper Sandler on Roivant Sciences (ROIV): 'Mosliciguat Ph2 PHocus Takes Center Stage & Catalyst-Rich 2026'
May 21, 2026 9:00 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $40 at Bernstein SocGen Group
May 21, 2026 8:55 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised at TD Cowen as 'IMVT-1402 Shines In D2T RA'
May 21, 2026 7:59 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
May 21, 2026 6:37 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $42 at Leerink
May 21, 2026 6:20 AM - StreetInsider
Form S-8 Roivant Sciences Ltd.
May 20, 2026 4:40 PM - SEC Filing
Form 10-K Roivant Sciences Ltd. For: Mar 31
May 20, 2026 7:17 AM - SEC Filing
Form 8-K Roivant Sciences Ltd. For: May 20
May 20, 2026 7:14 AM - SEC Filing
Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 57c
May 20, 2026 7:08 AM - StreetInsider
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: MORGAN STANLEY
May 12, 2026 1:20 PM - SEC Filing
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026 4:05 PM - StreetInsider
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: Ramaswamy Vivek
May 6, 2026 9:07 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Apr 20 Filed by: Venker Eric
April 22, 2026 6:28 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Apr 20 Filed by: Pulik Richard
April 22, 2026 6:27 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Apr 20 Filed by: Humes Jennifer
April 22, 2026 6:26 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Apr 17 Filed by: Oren Ilan
April 21, 2026 9:01 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Apr 17 Filed by: Epperly Melissa B,
April 21, 2026 6:34 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Apr 17 Filed by: MOMTAZEE JAMES C
April 21, 2026 6:33 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Apr 16 Filed by: Gline Matthew
April 20, 2026 6:27 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
April 20, 2026 4:17 PM - SEC Filing
Roivant Sciences (ROIV) PT Raised to $35 at JPMorgan
April 17, 2026 8:07 AM - StreetInsider
Form 144/A Roivant Sciences Ltd. Filed by: Gline Matthew
April 16, 2026 5:24 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Gline Matthew
April 16, 2026 4:34 PM - SEC Filing
Roivant Sciences (ROIV) PT Raised to $40 at Piper Sandler
April 16, 2026 7:11 AM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Apr 08 Filed by: Humes Jennifer
April 10, 2026 6:00 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Humes Jennifer
April 8, 2026 4:08 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Mar 31 Filed by: Torti Frank
April 2, 2026 7:15 PM - SEC Filing
Form 8-K Roivant Sciences Ltd. For: Apr 02
April 2, 2026 7:01 AM - SEC Filing
Priovant begins phase 2b/3 trial for brepocitinib in rare scalp disorder
April 2, 2026 5:00 AM - StreetInsider
Roivant starts new Phase 2b/3 trial for hair loss drug, TED study fails
April 2, 2026 5:00 AM - StreetInsider
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
April 2, 2026 5:00 AM - StreetInsider
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
April 2, 2026 5:00 AM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Mar 30 Filed by: Gline Matthew
April 1, 2026 7:21 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Mar 30 Filed by: Sukhatme Mayukh
April 1, 2026 7:19 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Mar 26 Filed by: Fitzgerald Meghan
March 30, 2026 9:01 PM - SEC Filing
Roivant Sciences (ROIV) Reiterated at Overweight by Cantor Fitzgerald After AAD Presentation
March 30, 2026 9:21 AM - StreetInsider
New England Journal of Medicine publishes VALOR trial results for brepocitinib
March 28, 2026 3:00 PM - StreetInsider
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026 3:00 PM - StreetInsider
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: VANGUARD GROUP INC
March 27, 2026 1:02 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Fitzgerald Meghan
March 26, 2026 4:15 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Mar 20 Filed by: Pulik Richard
March 24, 2026 7:09 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Mar 20 Filed by: Humes Jennifer
March 24, 2026 7:08 PM - SEC Filing
Form 8-K/A Roivant Sciences Ltd. For: Mar 03
March 23, 2026 8:45 AM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Mar 17 Filed by: Venker Eric
March 19, 2026 6:37 PM - SEC Filing
Bernstein SocGen Group Starts Immunovant (IMVT) at Market Perform
March 19, 2026 4:15 PM - StreetInsider
Bernstein SocGen Group Starts Roivant Sciences (ROIV) at Outperform
March 19, 2026 4:14 PM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Mar 16 Filed by: Epperly Melissa B,
March 18, 2026 6:23 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
March 17, 2026 4:18 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Epperly Melissa B,
March 16, 2026 4:04 PM - SEC Filing
Full Article List
